127 results on '"Robrecht, S."'
Search Results
2. A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX COMPARED TO OBINUTUZUMAB AND VENETOCLAX IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA
- Author
-
Kutsch, N., primary, Fink, A. M., additional, Robrecht, S., additional, Tausch, E., additional, Schneider, C., additional, Dierks, C., additional, Wendtner, C., additional, Meyer, R., additional, Gaska, T., additional, Chakupurakal, G., additional, Jentsch‐Ullrich, K., additional, Steiniger, H., additional, Schwaner, I., additional, Neumann, C., additional, Fischer, K., additional, Kreuzer, K., additional, Ritgen, M., additional, Stilgenbauer, S., additional, Hallek, M., additional, and Eichhorst, B., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Rare germline variants in ATM are associated with chronic lymphocytic leukemia
- Author
-
Tiao, G, Improgo, M R, Kasar, S, Poh, W, Kamburov, A, Landau, D-A, Tausch, E, Taylor-Weiner, A, Cibulskis, C, Bahl, S, Fernandes, S M, Hoang, K, Rheinbay, E, Kim, H T, Bahlo, J, Robrecht, S, Fischer, K, Hallek, M, Gabriel, S, Lander, E S, Stilgenbauer, S, Wu, C J, Kiezun, A, Getz, G, and Brown, J R
- Published
- 2017
- Full Text
- View/download PDF
4. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
- Author
-
Edelmann, J, Tausch, E, Landau, D A, Robrecht, S, Bahlo, J, Fischer, K, Fink, A M, Bloehdorn, J, Holzmann, K, Böttcher, S, Werner, L, Kneba, M, Gribben, J G, Neuberg, D S, Wu, C J, Hallek, M, Döhner, H, and Stilgenbauer, S
- Published
- 2017
- Full Text
- View/download PDF
5. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
- Author
-
Al-Sawaf, O, Robrecht, S, Bahlo, J, Fink, A M, Cramer, P, von Tresckow, J, Maurer, C, Bergmann, M, Seiler, T, Lange, E, Kneba, M, Stilgenbauer, S, Döhner, H, Kiehl, M G, Jäger, U, Wendtner, C M, Fischer, K, Goede, V, Hallek, M, Eichhorst, B, and Hopfinger, G
- Published
- 2017
- Full Text
- View/download PDF
6. P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
- Author
-
Cramer, P., primary, Fürstenau, M., additional, Giza, A., additional, Robrecht, S., additional, Tausch, E., additional, Schneider, C., additional, Wendtner, C.-M., additional, Hoechstetter, M., additional, Schetelig, J., additional, Böttcher, S., additional, Dreger, P., additional, Fink, A.-M., additional, Langerbeins, P., additional, Al-Sawaf, O., additional, Fischer, K., additional, Stilgenbauer, S., additional, Eichhorst, B., additional, and Hallek, M., additional
- Published
- 2022
- Full Text
- View/download PDF
7. P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Author
-
Hengeveld, P., primary, van der Klift, M., additional, Kolijn, P. M., additional, Davi, F., additional, Kavelaars, F., additional, de Jonge, E., additional, Robrecht, S., additional, Assmann, J., additional, van der Straten, L., additional, Ritgen, M., additional, Westerweel, P., additional, Fischer, K., additional, Goede, V., additional, Hallek, M., additional, Levin, M.-D., additional, and Langerak, A., additional
- Published
- 2022
- Full Text
- View/download PDF
8. S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
- Author
-
Al-Sawaf, O., primary, Zhang, C., additional, Robrecht, S., additional, Kotak, A., additional, Chang, N., additional, Fink, A.-M., additional, Tausch, E., additional, Schneider, C., additional, Ritgen, M., additional, Kreuzer, K.-A., additional, Chyla, B., additional, Eichhorst, B., additional, Jiang, Y., additional, Stilgenbauer, S., additional, Hallek, M., additional, and Fischer, K., additional
- Published
- 2022
- Full Text
- View/download PDF
9. S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB
- Author
-
Al-Sawaf, O., primary, Jin, H. Y., additional, Zhang, C., additional, Choi, Y., additional, Balasubramanian, S., additional, Robrecht, S., additional, Kotak, A., additional, Chang, N., additional, Fink, A.-M., additional, Tausch, E., additional, Schneider, C., additional, Ritgen, M., additional, Kreuzer, K.-A., additional, Chyla, B., additional, Paulson, J., additional, Eichhorst, B., additional, Stilgenbauer, S., additional, Jiang, Y., additional, Hallek, M., additional, and Fischer, K., additional
- Published
- 2022
- Full Text
- View/download PDF
10. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY.
- Author
-
Al‐Sawaf, O., Robrecht, S., Zhang, C., Olivieri, S., Chang, Y. M., Fink, A. M., Tausch, E., Schneider, C., Ritgen, M., Kreuzer, K., Sivcheva, L., Niemann, C., Schwarer, A., Loscertales, J., Weinkove, R., Strumberg, D., Kilfoyle, A., Runkel, E. D., Eichhorst, B., and Stilgenbauer, S.
- Subjects
CHRONIC lymphocytic leukemia ,SECONDARY primary cancer - Abstract
Progressive disease (PD) occurred in 67 cases in the Ven-Obi arm with 39 second-line treatments, and in 141 cases in the Clb-Obi arm (with 103 second-line treatments). B Background: b One-year fixed-duration venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL). Overall, 48 deaths were reported in the Ven-Obi arm (9 PD related) and 70 in the Clb-Obi arm (26 PD related); 6-year-OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR 0.69 [0.48-1.01], I p i = 0.052). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
11. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL.
- Author
-
Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Fink, A., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Schneider, C., Müller, L., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Zahn, M., and Dörfel, S.
- Subjects
CHRONIC lymphocytic leukemia ,ASYMPTOMATIC patients ,PLACEBOS ,RICHTER syndrome - Abstract
B Conclusions: b Early ibrutinib-treatment of patients with asymptomatic Binet stage A CLL at high risk of progression failed to demonstrate an overall survival benefit when compared to placebo. B Introduction: b We present the final analysis of the phase 3, double-blind, placebo-controlled CLL12 trial evaluating ibrutinib in patients with early stage CLL at increased risk of progression defined by a comprehensive score (NCT02863718). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
12. GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL
- Author
-
Tausch, E, primary, Schneider, C, additional, Yosifov, D, additional, Robrecht, S, additional, Zhang, C, additional, Al‐Sawaf, O, additional, Eichhorst, B, additional, Fink, A.‐M, additional, Bloehdorn, J, additional, Kreuzer, K.‐A, additional, Tandon, M, additional, Jiang, Y, additional, Kim, S. Y, additional, Porro Lura, M, additional, Döhner, H, additional, Fischer, K, additional, Hallek, M, additional, and Stilgenbauer, S, additional
- Published
- 2021
- Full Text
- View/download PDF
13. THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION
- Author
-
Al‐Sawaf, O., primary, Robrecht, S., additional, Stumpf, J., additional, Fink, A.‐M., additional, Ritgen, M., additional, Johansson, P., additional, Tausch, E., additional, Hoechstetter, M., additional, Staber, P., additional, Jäger, U., additional, Niemann, C. U., additional, Pallasch, C., additional, Kreuzer, K.‐A., additional, Stilgenbauer, S., additional, Fischer, K., additional, Wendtner, C., additional, Hallek, M., additional, and Eichhorst, B., additional
- Published
- 2021
- Full Text
- View/download PDF
14. BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG
- Author
-
Cramer, P, primary, Fürstenau, M, additional, Robrecht, S, additional, Giza, A, additional, Fink, A. M, additional, Fischer, K, additional, Langerbeins, P, additional, Al Sawaf, O, additional, Tausch, E, additional, Schneider, C, additional, Schetelig, J, additional, Dreger, P, additional, Böttcher, S, additional, Kreuzer, K. A, additional, Schilhabel, A, additional, Brüggemann, M, additional, Kneba, M, additional, Wendtner, C. M, additional, Stilgenbauer, S, additional, Eichhorst, B, additional, and Hallek, M, additional
- Published
- 2021
- Full Text
- View/download PDF
15. VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY
- Author
-
Al‐Sawaf, O, primary, Zhang, C, additional, Lu, T, additional, Liao, M. Z, additional, Panchal, A, additional, Robrecht, S, additional, Ching, T, additional, Tandon, M, additional, Fink, A.‐M, additional, Tausch, E, additional, Ritgen, M, additional, Böttcher, S, additional, Kreuzer, K.‐A, additional, Kim, S, additional, Miles, D, additional, Wendtner, C, additional, Stilgenbauer, S, additional, Eichhorst, B, additional, Jiang, Y, additional, Hallek, M, additional, and Fischer, K, additional
- Published
- 2021
- Full Text
- View/download PDF
16. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY
- Author
-
Al‐Sawaf, O., primary, Zhang, C., additional, Robrecht, S., additional, Tandon, M., additional, Panchal, A., additional, Fink, A.‐M., additional, Tausch, E., additional, Ritgen, M., additional, Kreuzer, K.‐A., additional, Kim, S., additional, Wendtner, C., additional, Eichhorst, B., additional, Stilgenbauer, S., additional, Jiang, Y., additional, Hallek, M., additional, and Fischer, K., additional
- Published
- 2021
- Full Text
- View/download PDF
17. The CLL-RT1 trial : A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation
- Author
-
Al-Sawaf, O., Robrecht, S., Fink, A., Ritgen, M., Johansson, P., Philipp Staber, Jaeger, U., Niemann, C., Pallasch, C., Kreuzer, K., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M., and Eichhorst, B.
- Subjects
Medizin - Published
- 2020
18. Lamin B1 regulates somatic mutations and progression of B-cell malignancies
- Author
-
Klymenko, T, Bloehdorn, J, Bahlo, J, Robrecht, S, Akylzhanova, G, Cox, K, Estenfelder, S, Wang, J, Edelmann, J, Strefford, J C, Wojdacz, T K, Fischer, K, Hallek, M, Stilgenbauer, S, Cragg, M, Gribben, J, and Braun, A
- Subjects
CHROMATIN ,B-Lymphocytes ,Chromatin Immunoprecipitation ,NUCLEAR LAMINA ,Lamin Type B ,CHRONIC LYMPHOCYTIC-LEUKEMIA ,HYPERMUTATION ,Immunoglobulin Variable Region ,CLL8 TRIAL ,Leukemia, Lymphocytic, Chronic, B-Cell ,MEMORY B ,PLASMA-CELLS ,Cell Line, Tumor ,Disease Progression ,AID ,Humans ,Original Article ,Somatic Hypermutation, Immunoglobulin ,Immunoglobulin Heavy Chains ,Lymphoma, Follicular ,IMMUNOGLOBULIN GENES ,GENE-EXPRESSION - Abstract
Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA sequence and diversify their antigen receptors. Here, we report that genome binding of Lamin B1, a component of the nuclear envelope involved in epigenetic chromatin regulation, is reduced during B-cell activation and formation of lymphoid germinal centres. Chromatin immunoprecipitation-Seq analysis showed that kappa and heavy variable immunoglobulin domains were released from the Lamin B1 suppressive environment when SHM was induced in B cells. RNA interference-mediated reduction of Lamin B1 resulted in spontaneous SHM as well as kappa-light chain aberrant surface expression. Finally, Lamin B1 expression level correlated with progression-free and overall survival in chronic lymphocytic leukaemia, and was strongly involved in the transformation of follicular lymphoma. In summary, here we report that Lamin B1 is a negative epigenetic regulator of SHM in normal B-cells and a 'mutational gatekeeper', suppressing the aberrant mutations that drive lymphoid malignancy.
- Published
- 2018
19. HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL
- Author
-
Al-Sawaf, O., primary, Lilienweiss, E., additional, Bahlo, J., additional, Robrecht, S., additional, Fink, A., additional, Patz, M., additional, Tandon, M., additional, Humphrey, K., additional, Jiang, Y., additional, Schary, W., additional, Porro Lurà, M., additional, Ritgen, M., additional, Tausch, E., additional, Stilgenbauer, S., additional, Eichhorst, B., additional, Fischer, K., additional, Hallek, M., additional, and Kreuzer, K., additional
- Published
- 2019
- Full Text
- View/download PDF
20. FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES
- Author
-
Fischer, K., primary, Porro Lurà, M., additional, Al-Sawaf, O., additional, Bahlo, J., additional, Fink, A., additional, Tandon, M., additional, Dixon, M., additional, Robrecht, S., additional, Warburton, S., additional, Humphrey, K., additional, Samoylova, O., additional, Liberati, A.M., additional, Pinilla-Ibarz, J., additional, Opat, S., additional, Sivcheva, L., additional, Le Dû, K., additional, Fogliatto, L.M., additional, Utoft Niemann, C., additional, Weinkove, R., additional, Robinson, S., additional, Kipps, T.J., additional, Boettcher, S., additional, Tausch, E., additional, Schary, W.L., additional, Eichhorst, B., additional, Wendtner, C., additional, Langerak, A.W., additional, Kreuzer, K., additional, Goede, V., additional, Stilgenbauer, S., additional, Mobasher, M., additional, Ritgen, M., additional, and Hallek, M., additional
- Published
- 2019
- Full Text
- View/download PDF
21. S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY
- Author
-
Tausch, E., primary, Bahlo, J., additional, Robrecht, S., additional, Schneider, C., additional, Bloehdorn, J., additional, Schrell, S., additional, Galler, C., additional, Al-Sawaf, O., additional, Fink, A.-M., additional, Eichhorst, B., additional, Kreuzer, K.-A., additional, Tandon, M., additional, Humphrey, K., additional, Jiang, Y., additional, Schary, W., additional, Porro Lurà, M., additional, Döhner, H., additional, Fischer, K., additional, Hallek, M., additional, and Stilgenbauer, S., additional
- Published
- 2019
- Full Text
- View/download PDF
22. S106 HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL
- Author
-
Al-Sawaf, O., primary, Lilienweiss, E., additional, Bahlo, J., additional, Robrecht, S., additional, Fink, A.-M., additional, Patz, M., additional, Tandon, M., additional, Humphrey, K., additional, Jiang, Y., additional, Schary, W.L., additional, Porro Lurà, M., additional, Ritgen, M., additional, Tasch, E., additional, Stilgenbauer, S., additional, Eichhorst, B., additional, Fischer, K., additional, Hallek, M., additional, and Kreuzer, K.-A., additional
- Published
- 2019
- Full Text
- View/download PDF
23. S149 FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES
- Author
-
Fischer, K., primary, Al-Sawaf, O., additional, Bahlo, J., additional, Fink, A.-M., additional, Tandon, M., additional, Dixon, M., additional, Robrecht, S., additional, Warburton, S., additional, Humphrey, K., additional, Samoylova, O., additional, Liberati, A.M., additional, Pinilla-Ibarz, J., additional, Opat, S., additional, Sivcheva, L., additional, Le DÛ, K., additional, Maria Fogliatto, L., additional, Utoft Niemann, C., additional, Weinkove, R., additional, Robinson, S., additional, Kipps, T.J., additional, Boettcher, S., additional, Tausch, E., additional, Schary, W.L., additional, Eichhorst, B., additional, Wendtner, C.-M., additional, Langerak, A.W., additional, Kreuzer, K.-A., additional, Goede, V., additional, Stilgenbauer, S., additional, Mobasher, M., additional, Ritgen, M., additional, and Hallek, M., additional
- Published
- 2019
- Full Text
- View/download PDF
24. GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient
- Author
-
Tausch, E., primary, Bahlo, J., additional, Robrecht, S., additional, Schneider, C., additional, Bloehdorn, J., additional, Schrell, S., additional, Galler, C., additional, Al-Sawaf, O., additional, Fink, A., additional, Eichhorst, B., additional, Kreuzer, K., additional, Tandon, M., additional, Humphrey, K., additional, Jiang, Y., additional, Schary, W., additional, Porro Lurà, M., additional, Döhner, H., additional, Fischer, K., additional, Hallek, M., additional, and Stilgenbauer, S., additional
- Published
- 2019
- Full Text
- View/download PDF
25. Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial.
- Author
-
Simon, F., Ligtvoet, R., Nösslinger, T., Bohn, J., von Tresckow, J., Liersch, R., Gaska, T., Jentsch‐Ullrich, K., Koenigsmann, M., Wolff, T., Schwaner, I., Wolf, D., Schneider, C., Tausch, E., Stilgenbauer, S., Kreuzer, K., Robrecht, S., Fink, A., Fürstenau, M., and Fischer, K.
- Subjects
CHRONIC lymphocytic leukemia - Abstract
B Introduction: b BTK-inhibitors have revolutionized treatment of CLL. Hoffmann-La Roche Ltd., Gilead, Janssen, Adapative Biotechnologies, Hexal Research funding: Abbvie, Beigene, AstraZeneca, Fa. Hoffmann-La Roche Ltd., Gilead, Janssen Educational grants: Abbvie, Beigene, AstraZeneca, Novartis, Celgene, Fa. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
26. Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemia.
- Author
-
Pachong, S. Mebwe, Robrecht, S., Ligtvoet, R., Tausch, E., Schneider, C., Fürstenau, M., von Tresckow, J., Huber, H., Stilgenbauer, S., Cramer, P., Eichhorst, B., Kreuzer, K., Hallek, M., Fischer, K., and Al‐Sawaf, O.
- Subjects
CHRONIC lymphocytic leukemia ,DEEP learning ,LEUCOCYTES - Abstract
Using digitized, genomically annotated peripheral blood smears (PBS) of patients with CLL, we evaluated whether deep learning can predict presence of I TP53 i aberrations (del[17p] and/or I TP53 mutation i ) and unmutated IGHV status solely based on cytomorphology. B Introduction: b Patient stratification based on genomic biomarkers is critical to optimize treatment of chronic lymphocytic leukemia (CLL). [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
27. Lamin B1 regulates somatic mutations and progression of B-cell malignancies
- Author
-
Klymenko, T, primary, Bloehdorn, J, additional, Bahlo, J, additional, Robrecht, S, additional, Akylzhanova, G, additional, Cox, K, additional, Estenfelder, S, additional, Wang, J, additional, Edelmann, J, additional, Strefford, J C, additional, Wojdacz, T K, additional, Fischer, K, additional, Hallek, M, additional, Stilgenbauer, S, additional, Cragg, M, additional, Gribben, J, additional, and Braun, A, additional
- Published
- 2017
- Full Text
- View/download PDF
28. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
- Author
-
Cramer, P., primary, von Tresckow, J., additional, Bahlo, J., additional, Robrecht, S., additional, Al-Sawaf, O., additional, Langerbeins, P., additional, Engelke, A., additional, Fink, A.M., additional, Fischer, K., additional, Seiler, T., additional, von Weikersthal, L.Fischer, additional, Hebart, H., additional, Kreuzer, K.A., additional, Ritgen, M., additional, Kneba, M., additional, Wendtner, C.M., additional, Stilgenbauer, S., additional, Eichhorst, B., additional, and Hallek, M., additional
- Published
- 2017
- Full Text
- View/download PDF
29. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
- Author
-
Edelmann, J, primary, Tausch, E, additional, Landau, D A, additional, Robrecht, S, additional, Bahlo, J, additional, Fischer, K, additional, Fink, A M, additional, Bloehdorn, J, additional, Holzmann, K, additional, Böttcher, S, additional, Werner, L, additional, Kneba, M, additional, Gribben, J G, additional, Neuberg, D S, additional, Wu, C J, additional, Hallek, M, additional, Döhner, H, additional, and Stilgenbauer, S, additional
- Published
- 2016
- Full Text
- View/download PDF
30. Rare germline variants in ATMare associated with chronic lymphocytic leukemia
- Author
-
Tiao, G, Improgo, M R, Kasar, S, Poh, W, Kamburov, A, Landau, D-A, Tausch, E, Taylor-Weiner, A, Cibulskis, C, Bahl, S, Fernandes, S M, Hoang, K, Rheinbay, E, Kim, H T, Bahlo, J, Robrecht, S, Fischer, K, Hallek, M, Gabriel, S, Lander, E S, Stilgenbauer, S, Wu, C J, Kiezun, A, Getz, G, and Brown, J R
- Published
- 2017
- Full Text
- View/download PDF
31. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
- Author
-
Eichhorst, B., Niemann, C. U., Kater, A. P., Fürstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., Schneider, C., Poulsen, C. B., Illmer, T., Schöttker, B., Nösslinger, T., and Janssens, A.
- Subjects
- *
CHRONIC lymphocytic leukemia , *VENETOCLAX , *PROGRESSION-free survival , *RITUXIMAB , *DISEASE progression - Abstract
BACKGROUND Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. METHODS In a phase 3, open-label trial, we randomly assigned, in a 1:1:1:1 ratio, fit patients with CLL who did not have TP53 aberrations to receive six cycles of chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) or 12 cycles of venetoclax–rituximab, venetoclax–obinutuzumab, or venetoclax–obinutuzumab–ibrutinib. Ibrutinib was discontinued after two consecutive measurements of undetectable minimal residual disease or could be extended. The primary end points were undetectable minimal residual disease (sensitivity, <10−4 [i.e., <1 CLL cell in 10,000 leukocytes]) as assessed by flow cytometry in peripheral blood at month 15 and progression-free survival. RESULTS A total of 926 patients were assigned to one of the four treatment regimens (229 to chemoimmunotherapy, 237 to venetoclax–rituximab, 229 to venetoclax–obinutuzumab, and 231 to venetoclax–obinutuzumab–ibrutinib). At month 15, the percentage of patients with undetectable minimal residual disease was significantly higher in the venetoclax–obinutuzumab group (86.5%; 97.5% confidence interval [CI], 80.6 to 91.1) and the venetoclax–obinutuzumab–ibrutinib group (92.2%; 97.5% CI, 87.3 to 95.7) than in the chemoimmunotherapy group (52.0%; 97.5% CI, 44.4 to 59.5; P<0.001 for both comparisons), but it was not significantly higher in the venetoclax–rituximab group (57.0%; 97.5% CI, 49.5 to 64.2; P=0.32). Three-year progression-free survival was 90.5% in the venetoclax–obinutuzumab–ibrutinib group and 75.5% in the chemoimmunotherapy group (hazard ratio for disease progression or death, 0.32; 97.5% CI, 0.19 to 0.54; P<0.001). Progression-free survival at 3 years was also higher with venetoclax–obinutuzumab (87.7%; hazard ratio for disease progression or death, 0.42; 97.5% CI, 0.26 to 0.68; P<0.001), but not with venetoclax–rituximab (80.8%; hazard ratio, 0.79; 97.5% CI, 0.53 to 1.18; P=0.18). Grade 3 and grade 4 infections were more common with chemoimmunotherapy (18.5%) and venetoclax–obinutuzumab–ibrutinib (21.2%) than with venetoclax–rituximab (10.5%) or venetoclax–obinutuzumab (13.2%). CONCLUSIONS Venetoclax–obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA–CLL13 ClinicalTrials.gov number, NCT02950051. opens in new tab; EudraCT number, 2015-004936-36. opens in new tab.) [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
- Author
-
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Le Du, K., Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., and Kipps, T. J.
- Subjects
- *
CHRONIC lymphocytic leukemia , *IMMUNOGLOBULIN genes , *PROGRESSION-free survival - Abstract
BACKGROUND The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known. METHODS In this open-label, phase 3 trial, we investigated fixed-duration treatment with venetoclax and obinutuzumab in patients with previously untreated CLL and coexisting conditions. Patients with a score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, with higher scores indicating more impaired function of organ systems) or a calculated creatinine clearance of less than 70 ml per minute were randomly assigned to receive venetoclax-obinutuzumab or chlorambucil- obinutuzumab. The primary end point was investigator-assessed progression- free survival. The safety of each regimen was also evaluated. RESULTS In total, 432 patients (median age, 72 years; median Cumulative Illness Rating Scale score, 8; median creatinine clearance, 66.4 ml per minute) underwent randomization, with 216 assigned to each group. After a median follow-up of 28.1 months, 30 primary end-point events (disease progression or death) had occurred in the venetoclax-obinutuzumab group and 77 had occurred in the chlorambucil-obinutuzumab group (hazard ratio, 0.35; 95% confidence interval [Cl], 0.23 to 0.53; P<0.001). The Kaplan-Meier estimate of the percentage of patients with progression- free survival at 24 months was significantly higher in the venetoclax-obinutuzumab group than in the chlorambucil-obinutuzumab group: 88.2% (95% Cl, 83.7 to 92.6) as compared with 64.1% (95% Cl, 57.4 to 70.8). This benefit was also observed in patients with TP53 deletion, mutation, or both and in patients with unmutated immunoglobulin heavy-chain genes. Grade 3 or 4 neutropenia occurred in 52.8% of patients in the venetoclax-obinutuzumab group and in 48.1% of patients in the chlorambucil-obinutuzumab group, and grade 3 or 4 infections occurred in 17.5% and 15.0%, respectively. All-cause mortality was 9.3% in the venetoclaxobinutuzumab group and 7.9% in the chlorambucil-obinutuzumab group. These differences were not significant. CONCLUSIONS Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
- Author
-
Kirsten Fischer, Barbara Eichhorst, Richard Rosenquist, Hartmut Döhner, Kostas Stamatopoulos, Paolo Ghia, Eugen Tausch, Michael Hallek, Sonia Jaramillo, Valentin Goede, Manuela Hoechstetter, Sandra Robrecht, Andreas Agathangelidis, Johannes Bloehdorn, Christof Schneider, Stephan Stilgenbauer, Jasmin Bahlo, Jaramillo, S., Agathangelidis, A., Schneider, C., Bahlo, J., Robrecht, S., Tausch, E., Bloehdorn, J., Hoechstetter, M., Fischer, K., Eichhorst, B., Goede, V., Hallek, M., Dohner, H., Rosenquist, R., Ghia, P., Stamatopoulos, K., and Stilgenbauer, S.
- Subjects
Oncology ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Article ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Internal medicine ,hemic and lymphatic diseases ,Medicine ,Humans ,Chronic Lymphocytic Leukemia ,Stereotyped subset ,Prospective Studies ,Prospective cohort study ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Hematology ,medicine.disease ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Clinical trial ,Leukemia ,030220 oncology & carcinogenesis ,Cohort ,Mutation ,business ,IGHV@ ,Immunoglobulin Heavy Chains ,030215 immunology - Abstract
Almost one-third of all patients with chronic lymphocytic leukemia (CLL) express stereotyped B-cell receptor immunoglobulins (BcR IG) and can be assigned to distinct subsets, each with a particular BcR IG. The largest stereotyped subsets are #1, #2, #4 and #8, associated with specific clinico-biological characteristics and outcomes in retrospective studies. We assessed the associations and prognostic value of these BcR IG in prospective multicenter clinical trials reflective of two different clinical situations: (i) early-stage patients ('watch and wait' arm of the CLL1 trial) (n=592); (ii) patients in need of treatment, enrolled in three phase III trials (CLL8, CLL10, CLL11), treated with different chemo-immunotherapies (n=1,861). Subset #1 was associated with del(11q), higher CLL International Prognostic Index (CLL-IPI) scores and similar clinical course to CLL with unmutated immunoglobulin heavy variable (IGHV) genes (U-CLL) in both early and advanced stage groups. IGHV-mutated (M-CLL) subset #2 cases had shorter time-to-first-treatment (TTFT) versus other M-CLL cases in the early-stage cohort (hazard ratio [HR]: 4.2, confidence interval [CI]: 2-8.6, P
- Published
- 2020
34. Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia.
- Author
-
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, Vehling-Kaiser U, Sivcheva L, Böttcher S, Dreger P, Illmer T, Gregor M, Staber PB, Stilgenbauer S, Niemann CU, Kater AP, Fischer K, Eichhorst B, Hallek M, and Al-Sawaf O
- Abstract
Purpose: Surrogate endpoints are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level analysis describes the correlation between progression-free survival (PFS) and minimal residual disease (MRD) with overall survival (OS) in first-line trials for CLL., Patients and Methods: First, patient-level correlation was confirmed using source data from 12 front-line GCLLSG-trials. Additionally, a joint-frailty copula model was fitted to validate correlation in the setting of targeted therapies.Second, a meta-analysis of first-line phase III trials in CLL from 2008-2024 was performed. Treatment effect correlation was quantified from seven GCLLSG and nine published trials, using hazard ratios for time-to-event and odds ratios for binary endpoints., Results: The GCLLSG analysis set comprised 4237 patients. Patient-level correlation for PFS/OS was strong with Spearman's Rho >0.9. The joint-frailty copula indicated a weak correlation for C/CIT with a tau of 0.52, (95% CI: 0.49 - 0.55) while the correlation was strong for TT (tau = 0.91, 95% CI: 0.89 - 0.93).The meta-analysis set contained a total of 8065 patients including 5198 (64%) patients treated with C/CIT and 2867 (36%) treated with TT. Treatment effect correlation of the hazard ratios (HR) for PFS and OS was R = 0.75 (95% CI: 0.74 - 0.76, R
2 = 0.56), while correlation of end-of-treatment MRD with PFS and OS was R = 0.88 (95%CI: -0.87 - 0.89; R2 = 0.78) and 0.71 (95%CI: 0.69 - 0.73; R2 = 0.5), respectively., Conclusion: Patient-level correlation was confirmed in the setting of targeted therapies while treatment-effect correlation between PFS and OS remains uncertain. MRD response status showed a high treatment-effect correlation with PFS but not OS, with the caveat of a limited number of randomized trials with available MRD data.- Published
- 2024
- Full Text
- View/download PDF
35. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
- Author
-
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kater AP, van der Spek E, Niemann CU, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Fischer K, Hallek M, and Eichhorst B
- Subjects
- Humans, Male, Female, Aged, Infections etiology, Infections chemically induced, Middle Aged, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell complications, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage
- Published
- 2024
- Full Text
- View/download PDF
36. Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
- Author
-
Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuß A, Vehling-Kaiser U, Koenigsmann M, Tausch E, Schneider C, Stilgenbauer S, Illmer T, Schlag R, Dörfel S, Gaska T, Kiehl M, Müller-Hagen S, Moorahrend E, Linde H, Schlenska-Lange A, von Tresckow J, Fischer K, Eichhorst B, Hallek M, and Fink AM
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Germany epidemiology, Aged, 80 and over, Adult, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Rituximab administration & dosage, Rituximab therapeutic use, Vidarabine analogs & derivatives, Vidarabine administration & dosage, Vidarabine therapeutic use, Cyclophosphamide therapeutic use, Cyclophosphamide administration & dosage, Registries, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
- Abstract
Long-term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long-term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first-line treatment with FCR were analyzed, of which 293 (70.3%) were treated outside of clinical trials. The median observation time from first-line was 95.8 (interquartile range 58.7-126.8) months. Focusing on data of 194 (46.5%) patients who received FCR first-line treatment after 2013 (start of data collection within GCLLSG registry), responses were documented in 85% of the patients, non-responses in 15%, and for 3.6% the assessment was missing. Median event-free survival (EFS, time until disease progression, subsequent treatment, or death) was 60.2 months with a 5-year EFS-rate of 50.6%. Patients with higher-risk disease, characterized by unmutated IGHV (N = 78), had a median EFS of 45.4 months with a 5-year EFS rate of 36.3%, while the median EFS was 77.5 months with a 5-year EFS rate of 60.3% in patients with mutated IGHV (N = 40). Median overall survival was not reached with a 5-year survival rate of 92.7%. In summary, first-line FCR was associated with long EFS, especially in patients exhibiting a mutated IGHV status., (© 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
37. The role of trephine bone marrow biopsies in the era of measurable residual disease - Results from the CLL10 trial of the German CLL Study Group (GCLLSG).
- Author
-
Kutsch N, Robrecht S, Fink A, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Clausen MR, Oschlies I, Ritgen M, Herling M, Fischer K, Döhner H, Wendtner CM, Kreuzer KA, Stilgenbauer S, Hallek M, Böttcher S, Klapper W, and Eichhorst B
- Abstract
Competing Interests: Nadine Kutsch: Honoraria: AbbVie, AstraZeneca, BMS, Kite/Gilead; Research support: AstraZeneca, Gilead. travel grants: AbbVie, AstraZeneca, Beigene, Celgene, Janssen. Sandra Robrecht: Honoraria: AstraZeneca. Anna Fink: Research funding: AstraZeneca and Celgene, Travel grants: AbbVie. Elisabeth Lange: no COIs. Rudolf Weide: Personal fees from AstraZeneca, BeiGene, Biotest, CSL Behring, Daiichi Sankyo, Eisai, Gilead, Hexal, Incyte, Medac, Menarini‐Stemline, Pierre Fabre, Roche, SeaGen, Sobi, and Takeda. Our institution has received research funding from Amgen, Biotest, Celgene, CSL Behring, Daiichi Sankyo, Eisai, GSK, Hexal, Lilly, Medac, Mundipharma, Octapharma, Sobi, and Takeda. Michael G. Kiehl: no COIs. Martin Sökler: no COIs. Rudolf Schlag: no COIs. Ursula Vehling‐Kaiser: no COIs. Georg Köchling: no COIs. Christoph Plöger: no COIs. Michael Gregor: no COIs. Torben Plesner: advisory board: Celgene/BMS. Michael R. Clausen: no COIs. Ilske Oschlies: no COIs. Matthias Ritgen: grants from F. Hoffman‐La Roche; and personal fees from F. Hoffmann‐La Roche and AbbVie. Marco Herling: no COIs. Kirsten Fischer: Advisory Board: AbbVie, Roche, AstaZeneca, Honoraria: Roche, AstraZeneca, Travel Support: Roche. Hartmut Döhner: Advisory role with honoraria for AbbVie, AstraZeneca, Gilead, Janssen, Jazz, Pfizer, Servier, Stemline, Syndax; clinical research funding (to institution) from AbbVie, Astellas, Bristol Myers Squibb, Celgene, Jazz Pharmaceuticals, Kronos Bio, Servier. Clemens‐Martin Wendtner: Research grants, advisory boards and travel grants by Hoffmann‐La Roche, Janssen‐Cilag, AstraZeneca, AbbVie, BeiGene and GSK. Karl‐Anton Kreuzer: consultant or advisory board member, honoraria and research support by AbbVie, Amgen, F. Hoffmann‐LaRoche, Gilead, Janssen‐Cilag and Mundipharma. Stephan Stilgenbauer: Advisory board, honoraria, research support, travel support, speaker fees, trial participation: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Celgene, Gilead, GSK, Hoffmann‐La Roche, Janssen, Lilly, Novartis, Sunesis. Michael Hallek: Consultant or advisory board member, honoraria, and research support by AbbVie, Amgen, Celgene, F. Hoffmann‐LaRoche, Gilead, Janssen‐Cilag and Mundipharma. Sebastian Böttcher: research funding from Janssen and AbbVie; and honoraria from Roche, Janssen, AbbVie, Novartis, Becton Dickinson, AstraZeneca, and Sanofi. Wolfram Klapper: Research grants from Roche, Amgen, Janssen, InCyte Regeneraon, Takeda and advisory role (Roche) paid to my institution. All without relevance for the current manuscript. Barbara Eichhorst: Consultant or advisory board member, research support or travel support by AbbVie, AstraZeneca, Celgene, F. Hoffmann‐LaRoche, Gilead, Janssen‐Cilag.
- Published
- 2024
- Full Text
- View/download PDF
38. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
- Author
-
Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, and Cramer P
- Subjects
- Humans, Aged, Middle Aged, Female, Male, Aged, 80 and over, Adult, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Sulfonamides administration & dosage, Sulfonamides therapeutic use, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Circulating Tumor DNA genetics, Circulating Tumor DNA blood, Pyrazines administration & dosage, Pyrazines therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Neoplasm, Residual, Benzamides administration & dosage, Benzamides therapeutic use
- Abstract
Abstract: The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax, and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chronic lymphocytic leukemia (CLL). MRD was measured by flow cytometry (FCM; undetectable MRD <10-4) in peripheral blood (PB) and circulating tumor DNA (ctDNA) using digital droplet polymerase chain reaction of variable-diversity-joining (VDJ) rearrangements and CLL-related mutations in plasma. The median number of previous treatments was 1 (range, 1-4); 18 patients (40%) had received a Bruton tyrosine kinase inhibitor (BTKi) and/or venetoclax before inclusion, 14 of 44 (31.8%) had TP53 aberrations, and 34 (75.6%) had unmutated immunoglobulin heavy-chain variable region genes. With a median observation time of 36.3 months and all patients off-treatment for a median of 21.9 months, uMRD <10-4 in PB was achieved in 42 of the 45 patients (93.3%) at any time point, including 17 of 18 (94.4%) previously exposed to venetoclax/BTKi and 13 of 14 (92.9%) with TP53 aberrations. The estimated 3-year progression-free and overall survival rates were 85.0% and 93.8%, respectively. Overall, 585 paired FCM/ctDNA samples were analyzed and 18 MRD recurrences (5 with and 13 without clinical progression) occurred after the end of treatment. Twelve samples were first detected by ctDNA, 3 by FCM, and 3 synchronously. In conclusion, time-limited MRD-guided acalabrutinib, venetoclax, and obinutuzumab achieved deep remissions in almost all patients with relapsed/refractory CLL. The addition of ctDNA-based analyses to FCM MRD assessment seems to improve early detection of relapses. This trial was registered at www.clinicaltrials.gov as #NCT03787264., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
39. Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study.
- Author
-
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivcheva L, Niemann CU, Schwarer AP, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek MJ, and Fischer K
- Abstract
Venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients with previously untreated chronic lymphocytic leukemia (CLL). In the CLL14 study, patients with previously untreated CLL and coexisting conditions were randomized to 12 cycles of Ven-Obi (n=216) or chlorambucil-obinutuzumab (Clb-Obi, n=216). Progression-free survival (PFS) was the primary endpoint. Key secondary endpoints included time-to-next-treatment (TTNT), rates of undetectable minimal residual disease (uMRD), overall survival (OS) and rates of adverse events. Patient reported outcomes (PROs) of time until definitive deterioration (TUDD) in quality of life (QoL) were analyzed. At a median observation time of 76.4 months, PFS remained superior for Ven-Obi compared to Clb-Obi (median 76.2 vs 36.4 months; HR 0.40[95%CI 0.31-0.52], p<0.0001). Likewise, TTNT was longer after Ven-Obi (6-year-TTNT 65.2% vs 37.1%; HR 0.44, 95%CI 0.33-0.58, p<0.0001). In the Ven-Obi arm, presence of del(17p), unmutated-IGHV and lymph node size ≥5 cm were independent prognostic factors for shorter PFS. Five years after treatment, 17 patients (7.9% of intention-to-treat-population) in the Ven-Obi arm had uMRD (<10-4 in peripheral blood) compared to 4 (1.9%) in the Clb-Obi arm. 6-year-OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR 0.69[95%CI 0.48-1.01], p=0.052). A significantly longer TUDD in global health status/QoL was observed in the Ven-Obi compared to the Clb-Obi arm (median 82.1 vs 65.1 months; HR 0.70[95%CI 0.51-0.97]). Follow-up adjusted SPM incidence rates were 2.3 and 1.4/1000 patient-months in the Ven-Obi and Clb-Obi arm, respectively. The sustained long-term survival, uMRD and QoL benefits support the use of one-year fixed-duration Ven-Obi in CLL. NCT02242942, EudraCT 2014-001810-24., (Copyright © 2024 American Society of Hematology.)
- Published
- 2024
- Full Text
- View/download PDF
40. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
- Author
-
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter M, Niemann CU, da Cunha-Bang C, Kater A, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, and Hallek M
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Prognosis, Aged, 80 and over, Adult, beta 2-Microglobulin, Survival Rate, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Leukemia, Lymphocytic, Chronic, B-Cell diagnosis, Molecular Targeted Therapy
- Abstract
Abstract: We evaluated the chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) in patients with CLL treated first line with targeted drugs (n = 991) or chemoimmunotherapy (n = 1256). With a median observation time of 40.5 months, the 3-year progression-free survival (PFS) rates for targeted drug-treated patients varied by CLL-IPI risk group: 96.5% (low), 87.6% (intermediate), 82.4% (high), and 78.7% (very high). Differences between consecutive CLL-IPI risk groups were observed for intermediate vs low and high vs intermediate, but not very high vs high. CLL-IPI factors β2-microglobulin, immunoglobulin heavy variable (IGHV) status, and TP53 status each retained prognostic value for PFS. The 3-year overall survival (OS) rates by CLL-IPI risk groups were 100%, 96%, 93.9%, and 89.4%, respectively, with no differences between consecutive risk groups. Age, Binet stage, β2-microglobulin, and TP53 status each retained prognostic value for OS. In chemoimmunotherapy patients (median observation time, 66.9 months), 3-year PFS rates for CLL-IPI risk groups were 78.1%, 51.4%, 40.1%, and 16.5%, respectively; corresponding 3-year OS rates were 97.4%, 93.1%, 81.8%, and 57.3%. In a matched-pair analysis, PFS differences in targeted therapies (n = 812) vs chemoimmunotherapy (n = 812) across all risk groups and OS differences in all but patients at low risk were demonstrated. The CLL-IPI maintains its prognostic value in predicting PFS outcomes with targeted drugs, but its impact in predicting survival appears diminished. Targeted therapies showed enhanced outcomes over chemoimmunotherapy, highlighting their effectiveness across various risk groups. Our findings support ongoing assessment of prognostic tools in CLL treatment evolution. These trials were registered at www.ClinicalTrials.gov as #NCT02345863, #NCT02401503, #NCT02689141, #NCT02445131, #NCT02758665, #NCT02950051, #NCT02242942, #NCT00262782, #NCT00281918, and #NCT01010061., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
41. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
- Author
-
Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, and Hallek M
- Subjects
- Humans, Aged, Male, Female, Middle Aged, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Purines administration & dosage, Purines therapeutic use, Purines adverse effects, Quinazolinones administration & dosage, Quinazolinones therapeutic use, Quinazolinones adverse effects, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage
- Published
- 2024
- Full Text
- View/download PDF
42. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
- Author
-
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, and Eichhorst B
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Follow-Up Studies, Rituximab administration & dosage, Rituximab adverse effects, Adenine analogs & derivatives, Adenine administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Progression-Free Survival, Cyclophosphamide administration & dosage, Pyrazoles administration & dosage, Pyrimidines administration & dosage, Immunotherapy, Adult, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Sulfonamides administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Piperidines administration & dosage, Vidarabine analogs & derivatives, Vidarabine administration & dosage
- Abstract
Background: In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates and progression-free survival compared with chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukaemia. However, to our knowledge, no data on direct comparisons of different venetoclax-based combinations are available., Methods: GAIA/CLL13 is an open-label, randomised, phase 3 study conducted at 159 sites in ten countries in Europe and the Middle East. Eligible patients were aged 18 years or older, with a life expectancy of at least 6 months, an Eastern Cooperative Oncology group performance status of 0-2, a cumulative illness rating scale score of 6 or lower or a single score of 4 or lower, and no TP53 aberrations. Patients were randomly assigned (1:1:1:1), with a computer-generated list stratified by age, Binet stage, and regional study group, to either chemoimmunotherapy, venetoclax-rituximab, venetoclax-obinutuzumab, or venetoclax-obinutuzumab-ibrutinib. All treatments were administered in 28-day cycles. Patients in the chemoimmunotherapy group received six cycles of treatment, with patients older than 65 years receiving intravenous bendamustine (90 mg/m
2 , days 1-2), whereas patients aged 65 years or younger received intravenous fludarabine (25 mg/m2 , days 1-3) and intravenous cyclophosphamide (250 mg/m2 , days 1-3). Intravenous rituximab (375 mg/m2 , day 1 of cycle 1; 500 mg/m2 , day 1 of cycles 2-6) was added to chemotherapy. In the experimental groups, patients received daily venetoclax (400 mg orally) for ten cycles after a 5-week ramp-up phase starting on day 22 of cycle 1. In the venetoclax-rituximab group, intravenous rituximab (375 mg/m2 , day 1 of cycle 1; 500 mg/m2 , day 1 of cycles 2-6) was added. In the obinutuzumab-containing groups, obinutuzumab was added (cycle 1: 100 mg on day 1, 900 mg on day 2, and 1000 mg on days 8 and 15; cycles 2-6: 1000 mg on day 1). In the venetoclax-obinutuzumab-ibrutinib group, daily ibrutinib (420 mg orally, from day 1 of cycle 1) was added until undetectable MRD was reached in two consecutive measurements (3 months apart) or until cycle 36. The planned treatment duration was six cycles in the chemoimmunotherapy group, 12 cycles in the venetoclax-rituximab and the venetoclax-obinutuzumab group and between 12 and 36 cycles in the venetoclax-obinutuzumab-ibrutinib group. Coprimary endpoints were the undetectable MRD rate in peripheral blood at month 15 for the comparison of venetoclax-obinutuzumab versus standard chemoimmunotherapy and investigator-assessed progression-free survival for the comparison of venetoclax-obinutuzumab-ibrutinib versus standard chemoimmunotherapy, both analysed in the intention-to-treat population (ie, all patients randomly assigned to treatment) with a split α of 0·025 for each coprimary endpoint. Both coprimary endpoints have been reported elsewhere. Here we report a post-hoc exploratory analysis of updated progression-free survival results after a 4-year follow-up of our study population. Safety analyses included all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT02950051, recruitment is complete, and all patients are off study treatment., Findings: Between Dec 13, 2016, and Oct 13, 2019, 1080 patients were screened and 926 were randomly assigned to treatment (chemoimmunotherapy group n=229; venetoclax-rituximab group n=237; venetoclax-obinutuzumab group n=229; and venetoclax-obinutuzumab-ibrutinib group n=231); mean age 60·8 years (SD 10·2), 259 (28%) of 926 patients were female, and 667 (72%) were male (data on race and ethnicity are not reported). At data cutoff for this exploratory follow-up analysis (Jan 31, 2023; median follow-up 50·7 months [IQR 44·6-57·9]), patients in the venetoclax-obinutuzumab group had significantly longer progression-free survival than those in the chemoimmunotherapy group (hazard ratio [HR] 0·47 [97·5% CI 0·32-0·69], p<0·0001) and the venetoclax-rituximab group (0·57 [0·38-0·84], p=0·0011). The venetoclax-obinutuzumab-ibrutinib group also had a significantly longer progression-free survival than the chemoimmunotherapy group (0·30 [0·19-0·47]; p<0·0001) and the venetoclax-rituximab group (0·38 [0·24-0·59]; p<0·0001). There was no difference in progression-free survival between the venetoclax-obinutuzumab-ibrutinib and venetoclax-obinutuzumab groups (0·63 [0·39-1·02]; p=0·031), and the proportional hazards assumption was not met for the comparison between the venetoclax-rituximab group versus the chemoimmunotherapy group (log-rank p=0·10). The estimated 4-year progression-free survival rate was 85·5% (97·5% CI 79·9-91·1; 37 [16%] events) in the venetoclax-obinutuzumab-ibrutinib group, 81·8% (75·8-87·8; 55 [24%] events) in the venetoclax-obinutuzumab group, 70·1% (63·0-77·3; 84 [35%] events) in the venetoclax-rituximab group, and 62·0% (54·4-69·7; 90 [39%] events) in the chemoimmunotherapy group. The most common grade 3 or worse treatment-related adverse event was neutropenia (114 [53%] of 216 patients in the chemoimmunotherapy group, 109 [46%] of 237 in the venetoclax-rituximab group, 127 [56%] of 228 in the venetoclax-obinutuzumab group, and 112 [48%] of 231 in the venetoclax-obinutuzumab-ibrutinib group). Deaths determined to be associated with study treatment by the investigator occurred in three (1%) patients in the chemoimmunotherapy group (n=1 due to each of sepsis, metastatic squamous cell carcinoma, and Richter's syndrome), none in the venetoclax-rituximab and venetoclax-obinutuzumab groups, and four (2%) in the venetoclax-obinutuzumab-ibrutinib group (n=1 due to each of acute myeloid leukaemia, fungal encephalitis, small-cell lung cancer, and toxic leukoencephalopathy)., Interpretation: With more than 4 years of follow-up, venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib significantly extended progression-free survival compared with both chemoimmunotherapy and venetoclax-rituximab in previously untreated, fit patients with chronic lymphocytic leukaemia, thereby supporting their use and further evaluation in this patient group, while still considering the higher toxicities observed with the triple combination., Funding: AbbVie, Janssen, and F Hoffmann-La Roche., Competing Interests: Declaration of interests MF reports research funding from AbbVie, AstraZeneca, BeiGene, Janssen, and Roche, and honoraria from AbbVie. JvT reports honoraria from AbbVie, BeiGene, Amgen, AstraZeneca, Janssen, Lilly, and Roche; travel grants from AbbVie, AstraZeneca, BeiGene, Roche, Lilly, and Janssen; and has received consulting fees from and participated on advisory boards for AbbVe, BeiGene, Amgen, and AstraZeneca. MG has received honoraria for participation in symposia and advisory boards from AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb (BMS)/Celgene, GSK, Novartis, Incyte, Janssen-Cilag, Jazz, Roche, Pfizer, Sanofi, and Servier; travel support from AbbVie, BeiGene, Pfizer, and Roche; all fees went to their institution. GJ has received honoraria from Astellas and AbbVie and participated on advisory boards for AbbVie and Servier. M-DL reports travel grants from AbbVie and Janssen. CdC-B reports consulting fees from Janssen, honoraria for lectures from Octapharma, support for attending meetings from AbbVie and Octapharma, and participation on advisory boards for Janssen, BeiGene, and AstraZeneca. CSchn reports speakers fees from AstraZeneca and AbbVie, travel support from AbbVie, and participation on an advisory board for Janssen. RB reports travel support from BeiGene, Janssen, and AbbVie, and honoraria for participation on an advisory board from AbbVie. TN reports honoraria for lectures or presentations and has participated at advisory boards from AbbVie, Roche, AstraZeneca, Gilead, BeiGene, and Janssen. CBP is the chairman of the Danish CLL group. HF reports research funding from Sanofi, Novartis, and Alexion and honoraria for lectures from Sanofi. NK reports research funding from AstraZeneca; honoraria from AbbVie, AstraZeneca, Kite/Gilead, BMS, and Lilly; and travel support from AbbVie, AstraZeneca, BeiGene, Lilly, and Janssen; and participation on advisory boards for AstraZeneca and Janssen. JD reports consulting fees, honoraria, and travel support from AbbVie and Janssen. SB reports honoraria from and participation on speakers bureaus for Roche, Janssen, AbbVie, AstraZeneca, and Sanofi; travel support from Janssen, BeiGene, and Roche; and research funding from Janssen and Miltenyi. FS reports speakers fees from AstraZeneca, travel support from Lilly, and research funding from AstraZeneca. A-MF reports research funding and honoraria from AstraZeneca and travel support from AbbVie. KF reports research grants from AbbVie and Roche, honoraria for advisory boards from AstraZeneca, and travel support from Roche. K-AK reports consulting fees, participation on speakers bureaus, and research funding from Roche, AbbVie, and Janssen. MR reports honoraria from Janssen, Roche, and AstraZeneca; consulting fees from Roche, Janssen, AstraZeneca, and AbbVie; research funding from AbbVie and Roche, and travel support from AstraZeneca. MBr reports research funding and consulting fees from Amgen; honoraria for speakers bureaus from Amgen, Becton Dickinson, Janssen, and Pfizer; travel support from Janssen; and participation on advisory boards for Incyte and Amgen. ET reports participation on advisory boards and honoraria from AbbVie, Janssen-Cilag, and BeiGene, AstraZeneca, and Roche; and travel support from AstraZeneca, AbbVie, BeiGene, Janssen. SS reports honoraria from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, and Sunesis; research funding from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, and Sunesis; travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis; and speaker fees from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, and Sunesis. MH reports consulting fees from Roche, Gilead, Janssen, BMS, AbbVie, and AstraZeneca and honoraria from Roche, Gilead, Janssen, BMS, AbbVie, and AstraZeneca. APK reports honoraria from AbbVie, AstraZeneca, BMS, Janssen, LAVA, and Roche/Genentech; travel grants from AbbVie and Janssen; research funding from AstraZeneca, Janssen, Roche/Genentech, AbbVie, and BMS. CUN reports research funding from Octapharma and AstraZeneca; consultancy and speaker fees from AbbVie, AstraZeneca, Janssen, Genmab, BeiGene, Octapharma, CSL Behring, Takeda, Lilly, and MSD; and participation on advisory boards for AstraZeneca, MSD, Genmab, and Janssen. BE reports consulting fees fromJanssen, AbbVie, Gilead, AstraZeneca, MSD, BeiGene, and Lilly; participation on speakers bureau for Roche, AbbVie, BeiGene, AstraZeneca, and MSD; honoraria from Roche, AbbVie, AstraZeneca, BeiGene, and MSD; research funding from Janssen, Gilead, Roche, AbbVie, BeiGene, and AstraZeneca; and travel support from BeiGene. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
43. Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
- Author
-
Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, Gruell H, Teipel F, Schlößer HA, Siepmann K, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Kolovou A, Cornely OA, Eichhorst B, Hallek M, and Langerbeins P
- Subjects
- Humans, SARS-CoV-2, COVID-19 Vaccines, Leukocytes, Mononuclear, Immunoglobulin G, Postoperative Complications, Vaccination, Adaptive Immunity, Antibodies, Viral, Leukemia, Lymphocytic, Chronic, B-Cell complications, Leukemia, Lymphocytic, Chronic, B-Cell therapy, COVID-19
- Abstract
Objective: Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL)., Methods/results: Blood samples of six patients with CLL were collected 55 days after fourth COVID-19 vaccination. All patients had a SARS-CoV-2 infection within 12 months before the second booster (fourth vaccination). SARS-CoV-2 spike receptor binding domain (RBD)-specific IgG antibodies were detectable in 6/6 (100.0%) CLL patients after four compared to 4/6 (66.7%) after three vaccinations. The median number of SARS-CoV-2 spike-specific T cells after repeated booster vaccination plus infection was 166 spot-forming cells (SFC) per million peripheral blood mononuclear cells. Overall, 5/5 (100%) studied patients showed a detectable increase in T cell activity., Conclusion: Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID-19 vaccination combined with SARS-CoV-2 infection, even in those undergoing B cell-depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants., (© 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
44. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
- Author
-
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, and Eichhorst B
- Subjects
- Humans, Middle Aged, Aged, Aged, 80 and over, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Piperidines, Pyrazoles, Pyrimidines, Antibodies, Monoclonal, Humanized
- Abstract
In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to chemotherapy and short survival. We initiated an international, investigator-initiated, prospective, open-label phase 2 study in which patients with RT received a combination of the PD-1 inhibitor tislelizumab plus the BTK inhibitor zanubrutinib for 12 cycles. Patients responding to treatment underwent maintenance treatment with both agents. The primary end point was overall response rate after six cycles. Of 59 enrolled patients, 48 patients received at least two cycles of treatment and comprised the analysis population according to the study protocol. The median observation time was 13.9 months, the median age was 67 (range 45-82) years. Ten patients (20.8%) had received previous RT-directed therapy. In total, 28 out of 48 patients responded to induction therapy with an overall response rate of 58.3% (95% confidence interval (CI) 43.2-72.4), including 9 (18.8%) complete reponse and 19 (39.6%) partial response, meeting the study's primary end point by rejecting the predefined null hypothesis of 40% (P = 0.008). Secondary end points included duration of response, progression-free survival and overall survival. The median duration of response was not reached, the median progression-free survival was 10.0 months (95% CI 3.8-16.3). Median overall survival was not reached with a 12-month overall survival rate of 74.7% (95% CI 58.4-91.0). The most common adverse events were infections (18.0%), gastrointestinal disorders (13.0%) and hematological toxicities (11.4%). These data suggest that combined checkpoint and BTK inhibition by tislelizumab plus zanubrutinib is an effective and well-tolerated treatment strategy for patients with RT. ClinicalTrials.gov Identifier: NCT04271956 ., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
45. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
- Author
-
von Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, Fischer K, Cramer P, Eichhorst B, Hallek M, and Fink AM
- Abstract
Idelalisib in combination with rituximab is an efficacious treatment for patients suffering from chronic lymphocytic leukemia (CLL) with known limitations due to toxicities. However, the benefit after prior Bruton tyrosine kinase inhibitor (BTKi) therapy remains unclear. For this analysis, 81 patients included in a non-interventional registry study of the German CLL study group (registered at www.clinicaltrials.gov as # NCT02863692) meeting the predefined criteria of a confirmed diagnosis of CLL and being treated with idelalisib containing regimens outside clinical trials were considered. 11 patients were treatment naïve (13.6%) and 70 patients (86.4%) pretreated. Patients had median of one prior therapy line (range 0-11). Median treatment duration with idelalisib was 5.1 months (range 0-55.0 months). Of 58 patients with documented treatment outcome, 39 responded to idelalisib containing therapy (67.2%). Patients treated with the BTKi ibrutinib as last prior treatment prior to idelalisib responded in 71.4% compared to a response rate of 61.9% in patients without prior ibrutinib. Median event free survival (EFS) was 15.9 months with a 16 versus 14 months EFS in patients with ibrutinib as last prior treatment or not, respectively. Median overall survival was 46.6 months. In conclusion, treatment with idelalisib appears to have a valuable impact in patients being refractory to prior ibrutinib therapy even though there are limitations in our analysis due to the low number of patients included., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
46. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
- Author
-
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, and Fischer K
- Published
- 2023
- Full Text
- View/download PDF
47. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
- Author
-
Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, and Stilgenbauer S
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics
- Abstract
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe regimen) in 41 previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation. Induction consisted of 6 cycles of GIVe; venetoclax and ibrutinib were continued up to cycle 12 as consolidation. Ibrutinib was given until cycle 15 or up to cycle 36 in patients not achieving a complete response and with detectable minimal residual disease. The primary end point was the complete remission rate at cycle 15, which was achieved at 58.5% (95% CI, 42.1-73.7; P < .001). The last patient reached the end of the study in January 2022. After a median observation time of 38.4 months (range, 3.7-44.9), the 36-month progression-free survival was 79.9%, and the 36-month overall survival was 92.6%. Only 6 patients continued ibrutinib maintenance. Adverse events of concern were neutropenia (48.8%, grade ≥3) and infections (19.5%, grade ≥3). Cardiovascular toxicity grade 3 occurred as atrial fibrillation at a rate of 2.4% between cycles 1 and 12, as well as hypertension (4.9%) between cycles 1 and 6. The incidence of adverse events of any grade and grade ≥3 was highest during induction and decreased over time. Progressive disease was observed in 7 patients between cycles 27 and 42. In conclusion, the CLL2-GIVe regimen is a promising fixed-duration, first-line treatment for patients with high-risk CLL with a manageable safety profile., (© 2023 by The American Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
48. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
- Author
-
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, and Kater AP
- Subjects
- Humans, Abnormal Karyotype, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Karyotype, Karyotyping, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics
- Abstract
Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in the context of venetoclax-based treatments is still debated. In this prospective analysis on karyotype complexity in CLL, we evaluated the impact of complex (≥3 chromosomal aberrations [CAs], CKTs) and highly complex karyotypes (≥5 CAs; hCKTs) as well as specific aberrations in previously untreated patients without TP53 aberrations undergoing either CIT or time-limited venetoclax-based therapies in the phase 3 GAIA/CLL13 trial. Karyotype analyses were available for 895 of 926 patients (96.7%), of whom 153 (17%) had a CKT and 43 (5%) hCKT. In the CIT arm, CKT was associated with shorter progression-free survival (PFS) (hazard ratio [HR] 2.58; 95% confidence interval [95% CI], 1.54-4.32; P < .001) and overall survival (HR, 3.25; 95% CI, 1.03-10.26; P = .044). In the pooled venetoclax arms, a multivariable analysis identified hCKTs (HR, 1.96; 95% CI, 1.03-3.72; P = .041), but not CKTs, as independent adverse prognosticators for PFS. The presence of translocations (unbalanced and/or balanced) was also independently associated with shorter PFSs in the venetoclax arms. CIT led to the acquisition of additional CAs (mean CAs, 2.0-3.4; from baseline to CLL progression), whereas karyotype complexity remained stable after venetoclax-based treatments (2.0, both time points). This analysis establishes highly complex karyotypes and translocations as adverse prognostic factors in the context of venetoclax-based combination treatments. The findings of this study support the incorporation of karyotyping into the standard diagnostic workup of CLL, because it identifies patients at high risk of poor treatment outcomes and thereby improves prognostication. This trial was registered at www.clinicaltrials.gov as #NCT02950051., (© 2023 by The American Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
49. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
- Author
-
Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk C, Grotenhuijs F, Müller T, Onder O, Wagle P, Herling CD, Kleppe M, Wang Z, Coombes KR, Robrecht S, Dalvi PS, Plosnita B, Mayer P, Abruzzo LV, Altmüller J, Gathof B, Persigehl T, Fischer K, Jebaraj B, Rienhoff HY, Ecker R, Zhao Y, Bruns CJ, Stilgenbauer S, Elenitoba-Johnson K, Hallek M, Schweiger MR, Odenthal M, Vasyutina E, and Herling M
- Subjects
- Humans, Mice, Animals, Histones metabolism, Lysine, Prospective Studies, Histone Demethylases genetics, Histone Demethylases metabolism, Tumor Microenvironment, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Abstract
In chronic lymphocytic leukemia (CLL), epigenetic alterations are considered to centrally shape the transcriptional signatures that drive disease evolution and underlie its biological and clinical subsets. Characterizations of epigenetic regulators, particularly histone-modifying enzymes, are very rudimentary in CLL. In efforts to establish effectors of the CLL-associated oncogene T-cell leukemia 1A (TCL1A), we identified here the lysine-specific histone demethylase KDM1A to interact with the TCL1A protein in B cells in conjunction with an increased catalytic activity of KDM1A. We demonstrate that KDM1A is upregulated in malignant B cells. Elevated KDM1A and associated gene expression signatures correlated with aggressive disease features and adverse clinical outcomes in a large prospective CLL trial cohort. Genetic Kdm1a knockdown in Eμ-TCL1A mice reduced leukemic burden and prolonged animal survival, accompanied by upregulated p53 and proapoptotic pathways. Genetic KDM1A depletion also affected milieu components (T, stromal, and monocytic cells), resulting in significant reductions in their capacity to support CLL-cell survival and proliferation. Integrated analyses of differential global transcriptomes (RNA sequencing) and H3K4me3 marks (chromatin immunoprecipitation sequencing) in Eμ-TCL1A vs iKdm1aKD;Eμ-TCL1A mice (confirmed in human CLL) implicate KDM1A as an oncogenic transcriptional repressor in CLL which alters histone methylation patterns with pronounced effects on defined cell death and motility pathways. Finally, pharmacologic KDM1A inhibition altered H3K4/9 target methylation and revealed marked anti-B-cell leukemic synergisms. Overall, we established the pathogenic role and effector networks of KDM1A in CLL via tumor-cell intrinsic mechanisms and its impacts in cells of the microenvironment. Our data also provide rationales to further investigate therapeutic KDM1A targeting in CLL., (© 2023 by The American Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
50. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
- Author
-
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, and Fischer K
- Subjects
- Humans, Transcriptome, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chlorambucil therapeutic use, Chlorambucil adverse effects, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics
- Abstract
Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized (1:1) to receive either 1-year venetoclax-obinutuzumab (Ven-Obi, 216 patients) or chlorambucil-Obi (Clb-Obi, 216 patients) therapy (NCT02242942). The primary endpoint was investigator-assessed progression-free survival (PFS); secondary endpoints included minimal residual disease (MRD) and overall survival. RNA sequencing of CD19-enriched blood was conducted for exploratory post-hoc analyses. After a median follow-up of 65.4 months, PFS is significantly superior for Ven-Obi compared to Clb-Obi (Hazard ratio [HR] 0.35 [95% CI 0.26-0.46], p < 0.0001). At 5 years after randomization, the estimated PFS rate is 62.6% after Ven-Obi and 27.0% after Clb-Obi. In both arms, MRD status at the end of therapy is associated with longer PFS. MRD + ( ≥ 10
-4 ) status is associated with increased expression of multi-drug resistance gene ABCB1 (MDR1), whereas MRD6 (< 10-6 ) is associated with BCL2L11 (BIM) expression. Inflammatory response pathways are enriched in MRD+ patient solely in the Ven-Obi arm. These data indicate sustained long-term efficacy of fixed-duration Ven-Obi in patients with previously untreated CLL. The distinct transcriptomic profile of MRD+ status suggests possible biological vulnerabilities., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.